Скачать или смотреть Cladribine vs S1P Modulators: Superior MS Treatment for Relapsing-Remitting Patients

Discover the latest study on Multiple Sclerosis treatments.
Cladribine outperforms S1P receptor modulators in reducing disability progression for treatment-naive relapsing-remitting MS patients.
Learn about the JAMA-published research comparing cladribine with S1P modulators, including key findings on NEDA-3, relapse rates, and MRI activity.
Explore the 25-month study involving 950 patients from Italian MS centers, highlighting cladribine's lower risk of disability worsening.
Understand secondary analyses on PIRA and RAW, plus long-term safety data from real-world cohorts.
Key keywords: Cladribine, S1P modulators, relapsing-remitting multiple sclerosis, MS treatment, disability progression, NEDA-3.
This video breaks down the comparative effectiveness, limitations, and implications for MS therapy choices.
Stay informed on breakthroughs in neurology and disease-modifying therapies for multiple sclerosis.